載入...
CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers
Although imatinib mesylate has been a major breakthrough in the treatment of advanced GIST, complete responses are rare and most patients eventually develop resistance to the drug. Thus the possibility of an imatinib-insensitive cell subpopulation within GIST tumors, harboring stem cell characterist...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3366284/ https://ncbi.nlm.nih.gov/pubmed/22076958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/gcc.20942 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|